This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammatory disease	Phosphoinositide 3-kinase- β (PI3K β); PI3K δ	<p>Mouse studies suggest that inhibiting both PI3Kβ and PI3Kδ could help treat inflammatory diseases. In a mouse model of severe rheumatoid arthritis (RA), deletion of both PI3Kβ and PI3Kδ decreased disease severity compared with that in mice lacking PI3Kβ or PI3Kδ. Next steps include developing dual inhibitors of PI3Kβ and PI3Kδ in collaboration with Karus Therapeutics Ltd.</p> <p>Karus' KAR4139, a small molecule inhibitor of PI3Kβ and PI3Kδ, is in lead optimization to treat inflammation and cancer.</p> <p>Gilead Sciences Inc.'s CAL-120, a small molecule inhibitor of PI3Kβ and PI3Kδ, is in preclinical development to treat cancer.</p> <p>SciBX 4(19); doi:10.1038/scibx.2011.544 Published online May 12, 2011</p>	Unpatented; available for licensing	<p>Kulkarni, S. <i>et al. Sci. Signaling</i>; published online April 12, 2011; doi:10.1126/scisignal.2001617</p> <p>Contact: Phillip T. Hawkins, The Babraham Institute, Cambridge, U.K. e-mail: phillip.hawkins@bbsrc.ac.uk</p> <p>Contact: Len R. Stephens, same affiliation as above e-mail: len.stephens@bbsrc.ac.uk</p>